Skip to main content
RAPS Convergence 2025 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Invitation Only
Invitation Only
Separate Ticket or Advanced Registration Required
Separate Ticket or Advanced Registration Required
Repeat Solutions Circle
Repeat Solutions Circle
Evaluation ViewAttendees 30

Sponsor Presentation

Sponsored Presentation: Navigating the ripple effects of FDA downsizing: What it means for life sciences in 2025

Wednesday, October 8, 2025
12:30 PM - 12:55 PM EST
Location/Room: Exhibit Hall: Ignite! Theater Booth 925
The FDA’s largest workforce reduction in decades is reshaping the U.S. regulatory landscape. With fewer resources and the potential for extended review cycles, organizations across pharmaceuticals, medical devices, and consumer health are facing heightened risks around compliance, product approvals, and operational agility, which could ultimately directly affect patient and consumer healthcare. This executive panel brings together leaders from the life sciences industry to share perspectives on what these changes mean and the bold strategies required to adapt.

Learning Objectives:

  • Assess how FDA workforce reductions are likely to affect approval and inspection timelines for drugs, devices, and prescription‑to‑OTC switches, and identify downstream impacts on patient access.
  • Apply risk‑based regulatory and quality strategies—including QMSR transition planning, inspection readiness tactics, and submission prioritization—to mitigate compliance gaps and market delays.
  • Leverage external expertise and redeployed FDA talent to maintain operational agility and innovation when agency resources are constrained.